Last updated: February 14, 2026
Market Analysis and Price Projections for NDC 60429-0918
Overview
The National Drug Code (NDC) 60429-0918 corresponds to Voxzogo (vosoritide), a drug developed by BioMarin Pharmaceutical for the treatment of achondroplasia, a form of dwarfism. It received FDA approval in August 2021. The drug targets a niche but growing market with limited competitors and favorable regulatory positioning.
Market Size and Growth
- Current Prevalence: Achondroplasia affects approximately 4,000 to 6,000 children and adults in the US. Globally, estimates range from 50,000 to 60,000 cases.
- Market Penetration: As of 2023, Voxzogo's adoption is limited primarily to specialized centers; uptake is expected to increase with increased physician awareness, pipeline expansion, and market access strategies.
- Growth Drivers: Growing diagnosis rates, increased awareness, and expanding indications (e.g., age groups and related skeletal dysplasias).
Competitive Landscape
- Existing Treatments: No direct competitors for disease-modifying treatment; growth hormone therapy offers limited efficacy.
- Pipeline Products: Several biotech firms researching analogs or alternative pathways, but none with regulatory approval in the indications for growth modulation.
- Market Differentiators: Unique mechanism of action targeting C-type natriuretic peptide (CNP) pathway. Regulatory exclusivity extends until 2036 after patent protections.
Pricing and Reimbursement Landscape
- Approved Price: The wholesale acquisition cost (WAC) for Voxzogo is approximately $435,000 annually per patient, reflecting a high-cost drug for a rare disease.
- Pricing Comparison: Similar gene therapies or enzyme replacement therapies for rare conditions range from $300,000 to $500,000 per year.
- Reimbursement: Payers recognize the significant clinical benefit, leading to coverage negotiations, especially in the US under Medicaid and private insurance programs.
Price Projections
- Short-term (2023-2025): Prices are unlikely to decrease sharply due to the drug's novelty, orphan drug status, and limited biosimilar competition.
- Long-term (2026-2030): Prices may face pressure from biosimilar entrants or pipeline competition, but barriers like patent protections and moderate manufacturing complexity mitigate immediate price erosion.
- Projected Range: Wholesale prices may stabilize between $430,000 and $470,000 annually, with potential discounts or value-based pricing arrangements.
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$435,000 |
Based on current WAC, prices remain stable |
| 2025 |
$430,000 - $450,000 |
Slight pressure due to payer negotiations |
| 2030 |
$410,000 - $470,000 |
Potential biosimilar entry and market adjustments |
Additional Factors Affecting Pricing
- Regulatory Exclusivity: Market exclusivity until 2036 under orphan drug designation.
- Manufacturing Costs: Moderate, but high costs for biological production persist.
- Market Access: Reimbursement gains depend on demonstrating long-term cost-effectiveness and quality-adjusted life years (QALYs) gained.
Key Takeaways
- The market is small but growing, driven by increased diagnosis, awareness, and limited competition.
- Current pricing is around $435,000 annually, with limited downward pressure expected soon.
- The drug's patent status and regulatory protections support sustained high prices through at least the late 2020s.
- Long-term price declines are possible if biosimilars or alternative treatments gain regulatory approval.
FAQs
Q1: What is the primary driver for Voxzogo’s market valuation?
The rarity of achondroplasia and the absence of approved disease-modifying therapies drive its market value and high pricing.
Q2: How does the price compare to other orphan drugs?
Voxzovo’s annual cost near $435,000 aligns with drugs like Zolgensma, which costs around $2.1 million but is a gene therapy for spinal muscular atrophy, reflecting differences in delivery and production.
Q3: Will biosimilar competition reduce prices?
Biologics face manufacturing complexity and patent protections; biosimilars are unlikely before 2036 but may impact prices afterward.
Q4: How does reimbursement influence market penetration?
Coverage varies by payer but generally favors access due to the drug's clinical benefits, supporting uptake growth.
Q5: Are there prospects for price reductions through value-based agreements?
Yes, payers may seek outcomes-based contracts to align payment with patient response, especially as long-term data accumulate.
References
[1] FDA. Voxzogo (vosoritide) approval announcement. 2021.
[2] BioMarin. Voxzogo prescribing information. 2021.
[3] IQVIA. Orphan drug market analysis. 2023.
[4] SSR Health. Biologic drug pricing. 2023.
